These days, with its revenue booming and a market cap swelling to twice the size of | Eli Lilly said it will spend $3 billion ...
AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...
Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a ...
AstraZeneca has refuted allegations its staff “refuse to cooperate and respect” the U.K. marketing code. | AstraZeneca has ...
Under the revised agreement, the two have taken their RSV commitment a step forward as Zhifei agrees to engage exclusively ...
Amid a flurry of manufacturing activity in the state this year, Amgen is the latest drugmaker to bolster its production ...
Last week, the immuno-oncology specialist revealed that part of the new setup will include CDMO services, as it will produce ...